Ernexa stock surges 40% on ovarian cancer trial results
Investing.com Gold reports: Ernexa stock surges 40% on ovarian cancer trial results. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Ernexa stock surges 40% on ovarian cancer trial results. Full body text was unavailable at ingest time, so this brief is based on headline context.